<DOC>
	<DOCNO>NCT02490241</DOCNO>
	<brief_summary>Lithium , gold standard treatment Bipolar Disorder ( BD ) common augmentation medication therapy Major Depression , commonly continued pregnancy due therapeutic benefit recent data suggest teratogenic effect lithium less historically believe . Due increase elimination lithium pregnancy , lithium concentration decrease blood woman BD vulnerable BD episode recurrence pregnancy . Uncontrolled symptom BD pregnancy increase risk postpartum exacerbation BD psychosis . Our study investigate pharmacokinetics ( PK ) lithium prior pregnancy , pregnancy , postpartum . Twenty woman take lithium pregnancy plan become pregnant continue lithium invite participate study measure repeat blood level lithium six time point preconception 3 month postpartum . The data collect inform dose , time dose , frequency dose lithium lead few untoward effect mother baby . Change elimination clearance lithium correlate symptom worsen develop dose algorithm help maintain wellness pregnant woman mood disorder .</brief_summary>
	<brief_title>Lithium Therapy : Understanding Mothers , Metabolism Mood</brief_title>
	<detailed_description>There increase risk recurrence Bipolar Disorder ( BD ) episodes worsen symptom pregnancy discontinuation mood stabilizer . Similarly , change medication concentration due physiological change pregnancy may effectively reduce medication dose thus efficacy pregnancy . Therapeutic dose monitoring proven great utility prevent seizure recurrence woman epilepsy ( WWE ) . Similar guideline woman epilepsy would benefit pregnant woman BD take mood stabilize medication pregnancy . Current evidence suggest lithium favorable reproductive profile many mood stabilize antiepileptic agent . However , pharmacokinetics well utility therapeutic dose monitor lithium pregnant patient Bipolar Disorder well study . This study observational protocol explore longitudinal pharmacokinetics ( PK ) lithium pregnancy postpartum 20 woman Bipolar Disorder . The correlation change bioavailability concentration ratios increase symptom depression , mania anxiety recurrence syndromal BD episode fulfill Diagnostic Statistics Manual Mental Disorders ( IV ) ( DSM4 ) criterion investigate . The primary aim study 1 . ) To describe change lithium elimination serum concentration across pregnancy postpartum establish efficacious use dosing requirement childbearing 2 . ) To evaluate association maternal umbilical cord lithium serum level . 3 . ) To explore relationship decline lithium serum concentration pregnancy increase psychiatric symptom recurrence syndromal BD . To optimize research yield investigation , participant option allow banking cerebrospinal ( CSF ) fluid DNA future analysis .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Age 18 old If Pregnant , equal less 26 week Englishspeaking DSMIV Bipolar Disorder , subtype , Major Depressive Disorder , Mood Disorder Not Otherwise Specified Able provide inform consent Daily dose lithium Active substance abuse within last 6 month and/or positive urine drug screen Active suicidality No obstetrical care Use drug affect metabolism lithium Medications FDA category F X antimanic drug Chronic Kidney Disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pregnant</keyword>
	<keyword>female</keyword>
	<keyword>woman</keyword>
	<keyword>lithium</keyword>
	<keyword>bipolar</keyword>
</DOC>